Earnings Alerts

M3 Inc (2413) Earnings: 2Q Net Sales and Income Surpass Estimates with Strong Yearly Growth

By November 12, 2025 No Comments
  • Net Sales Achievement: M3 Inc. reported second-quarter net sales of 84.69 billion yen, a 40% increase year-over-year, meeting the estimate of 84 billion yen.
  • Operating Income Growth: The operating income for the period was 16.22 billion yen, surpassing the estimate of 14.53 billion yen with a 34% year-over-year increase.
  • Net Income Surge: Net income rose by 80% year-over-year to 10.87 billion yen, exceeding the estimate of 9.27 billion yen.
  • First Half Results:
    • Medical Platform operating profit was 17.87 billion yen, a 22% increase, beating the estimate of 16.57 billion yen.
    • Evidence Solution operating profit rose 23% to 2.33 billion yen, slightly above the estimate of 2.28 billion yen.
    • Career Solution operating profit was 4.34 billion yen, a 6% increase, but below the estimate of 4.54 billion yen.
    • Site Solution operating profit declined 44% to 1.69 billion yen, missing the estimate of 2.42 billion yen.
    • Overseas operations saw a 34% increase with profits reaching 8.93 billion yen, surpassing the estimate of 8.56 billion yen.
    • Other Emerging Businesses operating profit was 578 million yen, marking a 56% increase year-over-year.
  • 2026 Year Forecast:
    • The company maintains its operating income forecast at 70.00 billion yen, below the estimate of 74.2 billion yen.
    • The net income forecast remains at 45.00 billion yen, slightly below the estimate of 47.23 billion yen.
    • Net sales forecast is kept at 360.00 billion yen, close to the estimate of 359.14 billion yen.
  • Market Sentiment: Analyst recommendations include 8 buy and 8 hold ratings, with no sell recommendations.

A look at M3 Inc Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth2
Resilience4
Momentum4
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, the long-term outlook for M3 Inc appears to be promising. With solid scores in Resilience and Momentum, the company demonstrates a strong ability to weather market fluctuations and sustain growth over time. While its Value, Dividend, and Growth scores are average, the higher scores in Resilience and Momentum suggest that M3 Inc is well-positioned to navigate challenges and capitalize on opportunities in the future.

M3, Inc. is a provider of medical information services for doctors online and offers support for pharmaceutical companies and medical equipment manufacturers. With a balanced set of Smart Scores, M3 Inc seems to have a stable foundation and the potential to thrive in the evolving landscape of healthcare services. Investors looking for a company with a good balance of resilience and growth prospects may find M3 Inc to be a promising long-term investment option.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars